AA-5-HTN-arachidonoylserotonin
FAAH inhibitor (IC50 5.6 µM) and TRPV1 antagonist (IC50 37 to 40 nM).
C₃₀H₄₂N₂O₂
CAS 187947-37-1
- Family
- ECS pharmacological toolEnzyme inhibitor
- Molar mass
- 462.70 g/mol
Updated on
In plain terms
N-arachidonoyl serotonin is a molecule that acts in two ways at once: it slows the enzyme that destroys anandamide, the cannabinoid made by the body, and it blocks a channel activated by capsaicin. Described in 1998 as a laboratory molecule, it was later detected in small amounts in the gut of pigs and mice. In rats and mice it showed analgesic activity in pain models; no study in humans was found.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to AA-5-HT: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of AA-5-HT.
FAAHFAAH found in 7 regions of the body
- CortexpresentCortical pyramidal neurons1
- Basal gangliapresentStriatal neurons1
- HypothalamuspresentPresent in hypothalamic nuclei1
- CerebellumpresentPurkinje cells and cerebellar layers1
- BrainstempresentInferior olivary nuclei1
- Adipose tissuepresentExpressed in mature adipocytes2
- BonepresentPresent on osteoclasts3
Map sources
- Romero J et al. Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res Mol Brain Res, 2002 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)
Cited values
- FAAHInhibitorIC50 = 5.6 µM · rat21 out of 100
Bisogno et al., Biochem Biophys Res Commun 1998 (new tab) · FAAH from RBL-2H3 cells (rat basophilic leukaemia), [14C]anandamide; 12.0 µM on FAAH from mouse N18TG2 neuroblastoma cells (the most active of the series, lower bound of the 12.0-26 µM range in the abstract); mixed-type, tight-binding, non-covalent inhibitor
- TRPV1AntagonistIC50 = 40 nM · rat and human57 out of 100
Maione et al., Br J Pharmacol 2007 (new tab) · recombinant TRPV1 in HEK-293 cells, against 100 nM capsaicin; 37 to 40 nM depending on species (the abstract does not attribute them); upper value retained
Measured effects
Not characterised. No placebo-controlled human trial has measured the effects of AA-5-HT, so no level is shown.
Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method
Pharmacology
N-arachidonoyl serotonin (AA-5-HT) inhibits FAAH and antagonises the TRPV1 channel. Bisogno and colleagues described it in 1998 among five artificially functionalised polyunsaturated fatty acids: it was the most active of the four new FAAH inhibitors reported (IC50 12.0 µM on FAAH from N18TG2 cells, 5.6 µM on that from RBL-2H3 cells). Resistant to hydrolysis by FAAH, it behaved as a tight-binding, non-covalent mixed inhibitor, with no effect on cytosolic phospholipase A2 or on anandamide uptake, and it did not activate CB1. In 2007, Maione and colleagues showed that it antagonises recombinant rat and human TRPV1 in HEK-293 cells (IC50 37 to 40 nM against 100 nM capsaicin) and that it had analgesic activity in the pain models used in rats and mice (formalin test, chronic constriction of the sciatic nerve in rats). This activity was partly linked to FAAH inhibition, elevated tissue anandamide and indirect CB1 activation (reversed by AM251), and also appeared to involve TRPV1 activation followed by desensitisation or direct antagonism of the channel (effects reversed by capsazepine and 5'-iodo-resiniferatoxin, or mimicked by them alone). These are preclinical results in rodents; no study in humans was found. An endogenous presence of AA-5-HT, with other N-acyl serotonins, has been reported in the jejunum and ileum of pigs and mice (Verhoeckx et al. 2011).
Key sources.
- Bisogno T et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun, 1998 (new tab)PMID 9703957
- Maione S et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol, 2007 (new tab)PMID 17279090
- Verhoeckx KC et al. Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract. Biochim Biophys Acta, 2011 (new tab)PMID 21798367
- PubChem, N-arachidonoylserotonin, CID 10027372 (identifiers and properties) (new tab)
History
- Source
- Described first as a synthetic compound: in 1998 it was one of five artificially functionalised polyunsaturated fatty acids (Bisogno et al. 1998). It was later detected as an endogenous compound, with other N-acyl serotonins, in the jejunum and ileum of pigs and mice (Verhoeckx et al. 2011). No authorised human use or circulation as a consumer product was found.
Origin
Research tool
No plant pathway. In pigs and mice, N-acyl serotonins including AA-5-HT form in intestinal tissue incubations, and this formation increases when serotonin is added; in mice, the pattern formed depends on the fatty acids of the diet (Verhoeckx et al. 2011). The abstract of that study does not name the responsible enzyme. Structurally it is an N-acyl serotonin: the amide of arachidonic acid and serotonin.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It is not listed in the schedules of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025, text reviewed). No marketing authorisation was found.
- France
Not classified: N-arachidonoyl serotonin is not on the ANSM consolidated list of narcotics (updated 16/02/2026). This fatty acid amide falls within none of the generic families of that list: the indole families require a substituent on the indole nitrogen and a methanone, carboxylate or carboxamide bridge carried by carbon 3, which is not the case. No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Enzyme inhibitor
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Arachidonoyl serotonin (new tab)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Bisogno T et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun, 1998 (new tab)PMID 9703957
- Maione S et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol, 2007 (new tab)PMID 17279090
- Verhoeckx KC et al. Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract. Biochim Biophys Acta, 2011 (new tab)PMID 21798367
- PubChem, N-arachidonoylserotonin, CID 10027372 (identifiers and properties) (new tab)
Identifiers
Names
- Common name
- N-arachidonoylserotonin
- Other names
- AA-5-HT · N-arachidonoyl serotonin · AA-5HT
Identifiers
- Formula
- C₃₀H₄₂N₂O₂
- CAS
- 187947-37-1
- PubChem CID
- 10027372(new tab)
- InChIKey
- QJDNHGXNNRLIGA-DOFZRALJSA-N
- SMILES
- CCCCC/C=
C\C/C= C\C/C= C\C/C= C\CCCC(= O) NCCC1= CNC2= C1C= C(C= C2) O
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.